

Breakfast Symposium of the
2016 Cutting Edge of Transplantation (CEOT) Meeting
sponsored by the American Society of Transplantation

Delayed Graft Function: Underlying Causes and Consequences

Phoenix, Arizona | February 26, 2016 | The Biltmore Hotel



Delayed Graft Function: Underlying Causes and Consequences

Meeting Overview:

Join us to learn about ongoing changes in the kidney transplant landscape and potential impact to the rate of delayed graft function (DGF) occurrence. We will discuss how the new landscape reflects increasing donor age, age matching, and regional organ sharing; the morbidity and mortality associated with DGF; the need for better options to treat and prevent DGF; the changing donor demographics for both deceased and live-donors and how this affects organ quality; and the multifactorial pathophysiology of DGF, including the role of complement-mediated and cell-mediated rejection. We will conclude with a live question-and-answer session moderated by our faculty panel.

Agenda

6:45 – 7:00 AM

Breakfast

7:00 – 7:05 AM

Welcome and Introductions

Judith Boice, PhD

7:05 – 7:25 AM

The New Transplant Landscape and DGF: Unintended Consequences

Lloyd Ratner, MD, MPH

7:25 – 7:45 AM

Complement as a Mediator of DGF

Steven Sacks, MD, PhD

7:45 – 8:00 AM

Question-and-Answer Session

Panel

8:00 AM

Meeting Adjournment

Faculty

The New Transplant Landscape and DGF: Unintended Consequences

Presenter: Lloyd Ratner, MD, MPH

Overview:

This presentation will briefly review the current kidney transplant landscape of increased donor age and evolving demographics, age matching, regional organ sharing/paired donations, and their potential effect on the incidence of DGF. We will learn the latest information on the morbidity and mortality associated with DGF, and how the increased utilization of marginal grafts to expand transplant access is increasing the need for better options to treat and prevent DGF.



Lloyd Ratner,
MD, MPH
Columbia University
New York, NY

Lloyd Ratner, MD, MPH, is Professor of Surgery and Director of Renal and Pancreatic Transplantation at Columbia University. Prior to joining the faculty at Columbia, Dr. Ratner was on the faculty of Johns Hopkins University in Baltimore, and served as the Chief of Solid Organ Transplantation at Thomas Jefferson University in Philadelphia.

Dr. Ratner originally hails from Brooklyn, NY, and received his undergraduate education from the State University of New York at Buffalo. After earning a medical degree at Hahnemann University, he obtained his general surgery training at Long Island Jewish Medical Center. He completed a fellowship in transplantation surgery and immunology at Washington University. In 2011, Dr. Ratner received a master of public health degree with a focus on healthcare policy, administration, and management.

Dr. Ratner has been a leading innovator in transplantation for the last two decades. In 1993, he performed the world's first dual renal transplant. In 1995 (with Dr. Louis Kavoussi), he performed the first laparoscopic donor nephrectomy, setting the stage for its widespread adoption, which resulted in a profound increase in living donor kidney transplantations. Dr. Ratner has made significant contributions to overcoming immunologic incompatibilities that have prohibited transplantation. He devised the plasmapheresis/IVIg protocol for alloantibody desensitization in 1998. In 2001, Dr. Ratner orchestrated the second paired kidney exchange in the United States. Subsequently, he arranged the first paired kidney exchanges in Pennsylvania and New York. More recently, Dr. Ratner has been a leading proponent of including compatible donor/recipient pairs in kidney exchanges. All of these strategies have increased organ availability and access to transplantation. For this work Dr. Ratner has received numerous awards and honors.

Dr. Ratner has authored or co-authored more than 160 peer-reviewed publications, and has been a federally funded investigator. He recently served as the Chairman of the Board of Directors of the LiveOnNY (formerly the New York Organ Donor Network), and has served on numerous national committees. He is a member of the Board of Directors of the United Network for Organ Sharing, and he presently serves as Treasurer of the American Society of Transplant Surgeons.

Complement as a Mediator of DGF

Presenter: *Steven Sacks, MD, PhD*

Overview:

This presentation will briefly review the multifactorial pathophysiology of ischemia/reperfusion injury and DGF, and will consider the role of mediators of DGF, including terminal complement. The presentation will include an outline of the complement system, the mechanisms of complement-mediated rejection, and the impact on cell-mediated rejection. Potential therapeutic targets in DGF and general principles of therapeutic targeting will also be presented.



Steven Sacks,
MD, PhD
King's College
London,
United Kingdom

Steven Sacks, MD, PhD, is a clinical nephrologist and researcher. He currently serves as Director of the MRC Centre for Transplantation, Head of the Division of Transplantation Immunology and Mucosal Biology at King's College London, and National Institute for Health Research Senior Investigator.

After receiving his undergraduate education and MB ChB from Bristol University, Dr. Sacks earned a PhD from Cambridge University and became a fellow of the Royal College of Physicians (FRCP). Most recently, he was elected a fellow of the United Kingdom Academy of Medical Sciences and was awarded the Fellowship of King's College.

Dr. Sacks' research focuses on how inflammation (complement) affects the results of transplantation of solid organs, tissues, and cells. Dr. Sacks set up Complement UK to facilitate research translation and training in degenerative and other diseases. He has a longstanding interest in ethical regulation of research and has particular expertise in first-in-man studies. He has served policy on the advancement of health research through work with the Medical Research Council and Arthritis Research UK, and as a fellow of the Academy of Medical Sciences.



Alexion® is a registered trademark of Alexion Pharmaceuticals, Inc. Copyright ©2016, Alexion Pharmaceuticals, Inc. All rights reserved. US/SOL-DGF/16/0001b